Febuxostat  ||| S:0 E:11 ||| NNP
for  ||| S:11 E:15 ||| IN
the  ||| S:15 E:19 ||| DT
treatment  ||| S:19 E:29 ||| NN
of  ||| S:29 E:32 ||| IN
hyperuricaemia  ||| S:32 E:47 ||| NN
in  ||| S:47 E:50 ||| IN
people  ||| S:50 E:57 ||| NNS
with  ||| S:57 E:62 ||| IN
gout ||| S:62 E:66 ||| NNS
:  ||| S:66 E:68 ||| :
a  ||| S:68 E:70 ||| DT
single  ||| S:70 E:77 ||| JJ
technology  ||| S:77 E:88 ||| NN
appraisal  ||| S:88 E:98 ||| VBD
This  ||| S:98 E:103 ||| DT
paper  ||| S:103 E:109 ||| NN
presents  ||| S:109 E:118 ||| VBZ
a  ||| S:118 E:120 ||| DT
summary  ||| S:120 E:128 ||| NN
of  ||| S:128 E:131 ||| IN
the  ||| S:131 E:135 ||| DT
evidence  ||| S:135 E:144 ||| NN
review  ||| S:144 E:151 ||| NN
group  ||| S:151 E:157 ||| NN
( ||| S:157 E:158 ||| -LRB-
ERG ||| S:158 E:161 ||| NNP
)  ||| S:161 E:163 ||| -RRB-
report  ||| S:163 E:170 ||| NN
into  ||| S:170 E:175 ||| IN
the  ||| S:175 E:179 ||| DT
clinical  ||| S:179 E:188 ||| JJ
effectiveness  ||| S:188 E:202 ||| NN
and  ||| S:202 E:206 ||| CC
cost-effectiveness  ||| S:206 E:225 ||| JJ
of  ||| S:225 E:228 ||| IN
febuxostat  ||| S:228 E:239 ||| NN
for  ||| S:239 E:243 ||| IN
the  ||| S:243 E:247 ||| DT
management  ||| S:247 E:258 ||| NN
of  ||| S:258 E:261 ||| IN
hyperuricaemia  ||| S:261 E:276 ||| NN
in  ||| S:276 E:279 ||| IN
patients  ||| S:279 E:288 ||| NNS
with  ||| S:288 E:293 ||| IN
gout  ||| S:293 E:298 ||| VBG
based  ||| S:298 E:304 ||| VBN
upon  ||| S:304 E:309 ||| IN
a  ||| S:309 E:311 ||| DT
review  ||| S:311 E:318 ||| NN
of  ||| S:318 E:321 ||| IN
the  ||| S:321 E:325 ||| DT
manufacturer ||| S:325 E:337 ||| NN
's  ||| S:337 E:340 ||| POS
submission  ||| S:340 E:351 ||| NN
to  ||| S:351 E:354 ||| TO
the  ||| S:354 E:358 ||| DT
National  ||| S:358 E:367 ||| NNP
Institute  ||| S:367 E:377 ||| NNP
for  ||| S:377 E:381 ||| IN
Health  ||| S:381 E:388 ||| NNP
and  ||| S:388 E:392 ||| CC
Clinical  ||| S:392 E:401 ||| NNP
Excellence  ||| S:401 E:412 ||| NNP
( ||| S:412 E:413 ||| -LRB-
NICE ||| S:413 E:417 ||| NNP
)  ||| S:417 E:419 ||| -RRB-
as  ||| S:419 E:422 ||| IN
part  ||| S:422 E:427 ||| NN
of  ||| S:427 E:430 ||| IN
the  ||| S:430 E:434 ||| DT
single  ||| S:434 E:441 ||| JJ
technology  ||| S:441 E:452 ||| NN
appraisal  ||| S:452 E:462 ||| NN
( ||| S:462 E:463 ||| -LRB-
STA ||| S:463 E:466 ||| NNP
)  ||| S:466 E:468 ||| -RRB-
process ||| S:468 E:475 ||| NN
.  ||| S:475 E:477 ||| .
The  ||| S:477 E:481 ||| DT
submission ||| S:481 E:491 ||| NN
's  ||| S:491 E:494 ||| POS
evidence  ||| S:494 E:503 ||| NN
came  ||| S:503 E:508 ||| VBD
from  ||| S:508 E:513 ||| IN
two  ||| S:513 E:517 ||| CD
randomised  ||| S:517 E:528 ||| NNS
controlled  ||| S:528 E:539 ||| VBN
trials  ||| S:539 E:546 ||| NNS
comparing  ||| S:546 E:556 ||| VBG
the  ||| S:556 E:560 ||| DT
efficacy  ||| S:560 E:569 ||| NN
and  ||| S:569 E:573 ||| CC
safety  ||| S:573 E:580 ||| NN
of  ||| S:580 E:583 ||| IN
febuxostat  ||| S:583 E:594 ||| NN
with  ||| S:594 E:599 ||| IN
allopurinol ||| S:599 E:610 ||| NN
.  ||| S:610 E:612 ||| .
The  ||| S:612 E:616 ||| DT
trials  ||| S:616 E:623 ||| NNS
were  ||| S:623 E:628 ||| VBD
of  ||| S:628 E:631 ||| IN
reasonable  ||| S:631 E:642 ||| JJ
methodological  ||| S:642 E:657 ||| JJ
quality  ||| S:657 E:665 ||| NN
and  ||| S:665 E:669 ||| CC
measured  ||| S:669 E:678 ||| VBN
a  ||| S:678 E:680 ||| DT
clinically  ||| S:680 E:691 ||| JJ
relevant  ||| S:691 E:700 ||| JJ
range  ||| S:700 E:706 ||| NN
of  ||| S:706 E:709 ||| IN
outcomes ||| S:709 E:717 ||| NNS
.  ||| S:717 E:719 ||| .
A  ||| S:719 E:721 ||| DT
pooled  ||| S:721 E:728 ||| JJ
clinical  ||| S:728 E:737 ||| JJ
efficacy  ||| S:737 E:746 ||| JJ
analysis  ||| S:746 E:755 ||| NN
showed  ||| S:755 E:762 ||| VBD
that  ||| S:762 E:767 ||| IN
a  ||| S:767 E:769 ||| DT
daily  ||| S:769 E:775 ||| JJ
dose  ||| S:775 E:780 ||| NN
of  ||| S:780 E:783 ||| IN
80  ||| S:783 E:786 ||| CD
mg  ||| S:786 E:789 ||| NNS
or  ||| S:789 E:792 ||| CC
120  ||| S:792 E:796 ||| CD
mg  ||| S:796 E:799 ||| NN
of  ||| S:799 E:802 ||| IN
febuxostat  ||| S:802 E:813 ||| NN
was  ||| S:813 E:817 ||| VBD
significantly  ||| S:817 E:831 ||| RB
more  ||| S:831 E:836 ||| RBR
effective  ||| S:836 E:846 ||| JJ
than  ||| S:846 E:851 ||| IN
fixed-dose  ||| S:851 E:862 ||| JJ
allopurinol  ||| S:862 E:874 ||| NNS
( ||| S:874 E:875 ||| -LRB-
300 ||| S:875 E:878 ||| CD
/ ||| S:878 E:879 ||| CD
100  ||| S:879 E:883 ||| CD
mg ||| S:883 E:885 ||| CD
/ ||| S:885 E:886 ||| CD
day ||| S:886 E:889 ||| NN
)  ||| S:889 E:891 ||| -RRB-
at  ||| S:891 E:894 ||| IN
lowering  ||| S:894 E:903 ||| VBG
serum  ||| S:903 E:909 ||| JJ
uric  ||| S:909 E:914 ||| JJ
acid  ||| S:914 E:919 ||| NN
( ||| S:919 E:920 ||| -LRB-
sUA ||| S:920 E:923 ||| NNP
)  ||| S:923 E:925 ||| -RRB-
levels  ||| S:925 E:932 ||| NNS
to  ||| S:932 E:935 ||| TO
therapeutic  ||| S:935 E:947 ||| JJ
targets  ||| S:947 E:955 ||| NNS
(  ||| S:955 E:956 ||| -LRB-
< ||| S:956 E:958 ||| SYM
6  ||| S:958 E:960 ||| CD
mg ||| S:960 E:962 ||| CD
/ ||| S:962 E:963 ||| CD
dl ||| S:963 E:965 ||| CD
) ||| S:965 E:966 ||| -RRB-
;  ||| S:966 E:968 ||| :
however ||| S:968 E:975 ||| RB
,  ||| S:975 E:977 ||| ,
a  ||| S:977 E:979 ||| DT
large  ||| S:979 E:985 ||| JJ
percentage  ||| S:985 E:996 ||| NN
of  ||| S:996 E:999 ||| IN
febuxostat  ||| S:999 E:1010 ||| JJ
patients  ||| S:1010 E:1019 ||| NNS
did  ||| S:1019 E:1023 ||| VBD
not  ||| S:1023 E:1027 ||| RB
achieve  ||| S:1027 E:1035 ||| VB
the  ||| S:1035 E:1039 ||| DT
primary  ||| S:1039 E:1047 ||| JJ
end  ||| S:1047 E:1051 ||| NN
point  ||| S:1051 E:1057 ||| NN
and  ||| S:1057 E:1061 ||| CC
the  ||| S:1061 E:1065 ||| DT
fixed-dose  ||| S:1065 E:1076 ||| JJ
allopurinol  ||| S:1076 E:1088 ||| JJ
regimen  ||| S:1088 E:1096 ||| NN
may  ||| S:1096 E:1100 ||| MD
have  ||| S:1100 E:1105 ||| VB
introduced  ||| S:1105 E:1116 ||| VBN
bias ||| S:1116 E:1120 ||| NN
.  ||| S:1120 E:1122 ||| .
There  ||| S:1122 E:1128 ||| EX
were  ||| S:1128 E:1133 ||| VBD
no  ||| S:1133 E:1136 ||| DT
differences  ||| S:1136 E:1148 ||| NNS
between  ||| S:1148 E:1156 ||| IN
treatments  ||| S:1156 E:1167 ||| NNS
in  ||| S:1167 E:1170 ||| IN
more  ||| S:1170 E:1175 ||| RBR
clinically  ||| S:1175 E:1186 ||| JJ
important  ||| S:1186 E:1196 ||| JJ
outcomes  ||| S:1196 E:1205 ||| JJ
such  ||| S:1205 E:1210 ||| JJ
as  ||| S:1210 E:1213 ||| IN
gout  ||| S:1213 E:1218 ||| JJ
flares  ||| S:1218 E:1225 ||| NN
and  ||| S:1225 E:1229 ||| CC
tophi  ||| S:1229 E:1235 ||| JJ
resolution  ||| S:1235 E:1246 ||| NN
after  ||| S:1246 E:1252 ||| IN
52  ||| S:1252 E:1255 ||| CD
weeks  ||| S:1255 E:1261 ||| NNS
of  ||| S:1261 E:1264 ||| IN
treatment ||| S:1264 E:1273 ||| NN
.  ||| S:1273 E:1275 ||| .
No  ||| S:1275 E:1278 ||| DT
subgroup  ||| S:1278 E:1287 ||| JJ
analyses  ||| S:1287 E:1296 ||| NNS
were  ||| S:1296 E:1301 ||| VBD
conducted  ||| S:1301 E:1311 ||| VBN
for  ||| S:1311 E:1315 ||| IN
patients  ||| S:1315 E:1324 ||| NNS
with  ||| S:1324 E:1329 ||| IN
renal  ||| S:1329 E:1335 ||| JJ
impairment ||| S:1335 E:1345 ||| NN
,  ||| S:1345 E:1347 ||| ,
non-responders  ||| S:1347 E:1362 ||| JJ
to  ||| S:1362 E:1365 ||| TO
allopurinol  ||| S:1365 E:1377 ||| VB
or  ||| S:1377 E:1380 ||| CC
patients  ||| S:1380 E:1389 ||| NNS
with  ||| S:1389 E:1394 ||| IN
severe  ||| S:1394 E:1401 ||| JJ
disease ||| S:1401 E:1408 ||| NN
.  ||| S:1408 E:1410 ||| .
Supplementary  ||| S:1410 E:1424 ||| JJ
data  ||| S:1424 E:1429 ||| NNS
from  ||| S:1429 E:1434 ||| IN
a  ||| S:1434 E:1436 ||| DT
2-year  ||| S:1436 E:1443 ||| JJ
open-label  ||| S:1443 E:1454 ||| JJ
extension  ||| S:1454 E:1464 ||| NN
study  ||| S:1464 E:1470 ||| NN
were  ||| S:1470 E:1475 ||| VBD
also  ||| S:1475 E:1480 ||| RB
provided ||| S:1480 E:1488 ||| VBN
,  ||| S:1488 E:1490 ||| ,
but  ||| S:1490 E:1494 ||| CC
were  ||| S:1494 E:1499 ||| VBD
difficult  ||| S:1499 E:1509 ||| JJ
to  ||| S:1509 E:1512 ||| TO
interpret  ||| S:1512 E:1522 ||| VB
and  ||| S:1522 E:1526 ||| CC
poorly  ||| S:1526 E:1533 ||| RB
reported ||| S:1533 E:1541 ||| VBD
.  ||| S:1541 E:1543 ||| .
The  ||| S:1543 E:1547 ||| DT
incidence  ||| S:1547 E:1557 ||| NN
of  ||| S:1557 E:1560 ||| IN
adverse  ||| S:1560 E:1568 ||| JJ
events  ||| S:1568 E:1575 ||| NNS
was  ||| S:1575 E:1579 ||| VBD
similar  ||| S:1579 E:1587 ||| JJ
between  ||| S:1587 E:1595 ||| IN
treatments ||| S:1595 E:1605 ||| NNS
,  ||| S:1605 E:1607 ||| ,
although  ||| S:1607 E:1616 ||| IN
more  ||| S:1616 E:1621 ||| RBR
febuxostat  ||| S:1621 E:1632 ||| JJ
recipients  ||| S:1632 E:1643 ||| NNS
discontinued  ||| S:1643 E:1656 ||| VBN
treatment  ||| S:1656 E:1666 ||| NN
prematurely ||| S:1666 E:1677 ||| RB
.  ||| S:1677 E:1679 ||| .
A  ||| S:1679 E:1681 ||| DT
decision  ||| S:1681 E:1690 ||| NN
tree  ||| S:1690 E:1695 ||| NN
model  ||| S:1695 E:1701 ||| NN
was  ||| S:1701 E:1705 ||| VBD
developed  ||| S:1705 E:1715 ||| VBN
to  ||| S:1715 E:1718 ||| TO
determine  ||| S:1718 E:1728 ||| VB
the  ||| S:1728 E:1732 ||| DT
cost-effectiveness  ||| S:1732 E:1751 ||| JJ
of  ||| S:1751 E:1754 ||| IN
febuxostat ||| S:1754 E:1764 ||| NN
.  ||| S:1764 E:1766 ||| .
The  ||| S:1766 E:1770 ||| DT
scope  ||| S:1770 E:1776 ||| NN
was  ||| S:1776 E:1780 ||| VBD
limited  ||| S:1780 E:1788 ||| VBN
to  ||| S:1788 E:1791 ||| TO
the  ||| S:1791 E:1795 ||| DT
comparison  ||| S:1795 E:1806 ||| NN
of  ||| S:1806 E:1809 ||| IN
continual  ||| S:1809 E:1819 ||| JJ
febuxostat  ||| S:1819 E:1830 ||| JJ
treatment  ||| S:1830 E:1840 ||| NN
with  ||| S:1840 E:1845 ||| IN
continual  ||| S:1845 E:1855 ||| JJ
allopurinol  ||| S:1855 E:1867 ||| JJ
treatment ||| S:1867 E:1876 ||| NN
.  ||| S:1876 E:1878 ||| .
Switching  ||| S:1878 E:1888 ||| VBG
between  ||| S:1888 E:1896 ||| IN
treatments  ||| S:1896 E:1907 ||| NNS
or  ||| S:1907 E:1910 ||| CC
withdrawing  ||| S:1910 E:1922 ||| JJ
treatment  ||| S:1922 E:1932 ||| NN
in  ||| S:1932 E:1935 ||| IN
patients  ||| S:1935 E:1944 ||| NNS
whose  ||| S:1944 E:1950 ||| WP$
sUA  ||| S:1950 E:1954 ||| JJ
levels  ||| S:1954 E:1961 ||| NNS
had  ||| S:1961 E:1965 ||| VBD
not  ||| S:1965 E:1969 ||| RB
decreased  ||| S:1969 E:1979 ||| VBN
was  ||| S:1979 E:1983 ||| VBD
not  ||| S:1983 E:1987 ||| RB
permitted ||| S:1987 E:1996 ||| VBN
.  ||| S:1996 E:1998 ||| .
The  ||| S:1998 E:2002 ||| DT
model  ||| S:2002 E:2008 ||| NN
predicted  ||| S:2008 E:2018 ||| VBD
a  ||| S:2018 E:2020 ||| DT
cost-effectiveness  ||| S:2020 E:2039 ||| JJ
of  ||| S:2039 E:2042 ||| IN
16,324  ||| S:2042 E:2049 ||| CD
pounds  ||| S:2049 E:2056 ||| NNS
[ ||| S:2056 E:2057 ||| -LRB-
95 ||| S:2057 E:2059 ||| CD
%  ||| S:2059 E:2061 ||| NN
confidence  ||| S:2061 E:2072 ||| NN
interval  ||| S:2072 E:2081 ||| NNS
( ||| S:2081 E:2082 ||| -LRB-
CI ||| S:2082 E:2084 ||| NNP
)  ||| S:2084 E:2086 ||| -RRB-
6281  ||| S:2086 E:2091 ||| CD
pounds  ||| S:2091 E:2098 ||| NNS
to  ||| S:2098 E:2101 ||| TO
239,928  ||| S:2101 E:2109 ||| CD
pounds ||| S:2109 E:2115 ||| NNS
]  ||| S:2115 E:2117 ||| -RRB-
per  ||| S:2117 E:2121 ||| FW
quality-adjusted  ||| S:2121 E:2138 ||| FW
life-year  ||| S:2138 E:2148 ||| FW
( ||| S:2148 E:2149 ||| -LRB-
QALY ||| S:2149 E:2153 ||| NNP
)  ||| S:2153 E:2155 ||| -RRB-
gained  ||| S:2155 E:2162 ||| VBD
for  ||| S:2162 E:2166 ||| IN
febuxostat  ||| S:2166 E:2177 ||| VBG
compared  ||| S:2177 E:2186 ||| VBN
with  ||| S:2186 E:2191 ||| IN
allopurinol  ||| S:2191 E:2203 ||| NN
after  ||| S:2203 E:2209 ||| IN
2  ||| S:2209 E:2211 ||| CD
years  ||| S:2211 E:2217 ||| NNS
of  ||| S:2217 E:2220 ||| IN
treatment ||| S:2220 E:2229 ||| NN
.  ||| S:2229 E:2231 ||| .
The  ||| S:2231 E:2235 ||| DT
incremental  ||| S:2235 E:2247 ||| JJ
cost  ||| S:2247 E:2252 ||| NN
per  ||| S:2252 E:2256 ||| IN
QALY  ||| S:2256 E:2261 ||| NNP
was  ||| S:2261 E:2265 ||| VBD
below  ||| S:2265 E:2271 ||| IN
20,000  ||| S:2271 E:2278 ||| CD
pounds  ||| S:2278 E:2285 ||| NNS
in  ||| S:2285 E:2288 ||| IN
63 ||| S:2288 E:2290 ||| CD
%  ||| S:2290 E:2292 ||| NN
of  ||| S:2292 E:2295 ||| IN
the  ||| S:2295 E:2299 ||| DT
simulations  ||| S:2299 E:2311 ||| JJ
undertaken ||| S:2311 E:2321 ||| NN
.  ||| S:2321 E:2323 ||| .
Changes  ||| S:2323 E:2331 ||| NNS
in  ||| S:2331 E:2334 ||| IN
the  ||| S:2334 E:2338 ||| DT
time  ||| S:2338 E:2343 ||| NN
horizon  ||| S:2343 E:2351 ||| NN
did  ||| S:2351 E:2355 ||| VBD
not  ||| S:2355 E:2359 ||| RB
materially  ||| S:2359 E:2370 ||| RB
affect  ||| S:2370 E:2377 ||| VB
the  ||| S:2377 E:2381 ||| DT
results ||| S:2381 E:2388 ||| NNS
.  ||| S:2388 E:2390 ||| .
The  ||| S:2390 E:2394 ||| DT
ERG  ||| S:2394 E:2398 ||| NNP
believes  ||| S:2398 E:2407 ||| VBZ
that  ||| S:2407 E:2412 ||| IN
the  ||| S:2412 E:2416 ||| DT
modelling  ||| S:2416 E:2426 ||| JJ
structure  ||| S:2426 E:2436 ||| NN
employed  ||| S:2436 E:2445 ||| NNS
was  ||| S:2445 E:2449 ||| VBD
not  ||| S:2449 E:2453 ||| RB
appropriate  ||| S:2453 E:2465 ||| JJ
to  ||| S:2465 E:2468 ||| TO
estimate  ||| S:2468 E:2477 ||| VB
the  ||| S:2477 E:2481 ||| DT
cost-effectiveness  ||| S:2481 E:2500 ||| JJ
of  ||| S:2500 E:2503 ||| IN
febuxostat  ||| S:2503 E:2514 ||| NN
within  ||| S:2514 E:2521 ||| IN
a  ||| S:2521 E:2523 ||| DT
treatment  ||| S:2523 E:2533 ||| NN
algorithm ||| S:2533 E:2542 ||| NN
.  ||| S:2542 E:2544 ||| .
In  ||| S:2544 E:2547 ||| IN
addition ||| S:2547 E:2555 ||| NN
,  ||| S:2555 E:2557 ||| ,
there  ||| S:2557 E:2563 ||| EX
were  ||| S:2563 E:2568 ||| VBD
concerns  ||| S:2568 E:2577 ||| NNS
about  ||| S:2577 E:2583 ||| IN
the  ||| S:2583 E:2587 ||| DT
methodology  ||| S:2587 E:2599 ||| NN
used  ||| S:2599 E:2604 ||| VBN
for  ||| S:2604 E:2608 ||| IN
collecting  ||| S:2608 E:2619 ||| VBG
data  ||| S:2619 E:2624 ||| NNS
on  ||| S:2624 E:2627 ||| IN
key  ||| S:2627 E:2631 ||| JJ
model  ||| S:2631 E:2637 ||| NN
inputs ||| S:2637 E:2643 ||| NNS
.  ||| S:2643 E:2645 ||| .
Given  ||| S:2645 E:2651 ||| VBN
these  ||| S:2651 E:2657 ||| DT
reservations  ||| S:2657 E:2670 ||| NNS
the  ||| S:2670 E:2674 ||| DT
cost-effectiveness  ||| S:2674 E:2693 ||| JJ
of  ||| S:2693 E:2696 ||| IN
febuxostat  ||| S:2696 E:2707 ||| NNS
could  ||| S:2707 E:2713 ||| MD
not  ||| S:2713 E:2717 ||| RB
be  ||| S:2717 E:2720 ||| VB
determined ||| S:2720 E:2730 ||| VBN
.  ||| S:2730 E:2732 ||| .
The  ||| S:2732 E:2736 ||| DT
guidance  ||| S:2736 E:2745 ||| NN
issued  ||| S:2745 E:2752 ||| VBN
by  ||| S:2752 E:2755 ||| IN
NICE  ||| S:2755 E:2760 ||| NNP
in  ||| S:2760 E:2763 ||| IN
August  ||| S:2763 E:2770 ||| NNP
2008  ||| S:2770 E:2775 ||| CD
as  ||| S:2775 E:2778 ||| IN
a  ||| S:2778 E:2780 ||| DT
result  ||| S:2780 E:2787 ||| NN
of  ||| S:2787 E:2790 ||| IN
the  ||| S:2790 E:2794 ||| DT
STA  ||| S:2794 E:2798 ||| NNP
states  ||| S:2798 E:2805 ||| NNS
that  ||| S:2805 E:2810 ||| IN
febuxostat  ||| S:2810 E:2821 ||| NN
is  ||| S:2821 E:2824 ||| VBZ
recommended  ||| S:2824 E:2836 ||| VBN
as  ||| S:2836 E:2839 ||| IN
an  ||| S:2839 E:2842 ||| DT
option  ||| S:2842 E:2849 ||| NN
for  ||| S:2849 E:2853 ||| IN
the  ||| S:2853 E:2857 ||| DT
management  ||| S:2857 E:2868 ||| NN
of  ||| S:2868 E:2871 ||| IN
chronic  ||| S:2871 E:2879 ||| JJ
hyperuricaemia  ||| S:2879 E:2894 ||| NN
in  ||| S:2894 E:2897 ||| IN
gout  ||| S:2897 E:2902 ||| VBG
only  ||| S:2902 E:2907 ||| RB
for  ||| S:2907 E:2911 ||| IN
people  ||| S:2911 E:2918 ||| NNS
who  ||| S:2918 E:2922 ||| WP
are  ||| S:2922 E:2926 ||| VBP
intolerant  ||| S:2926 E:2937 ||| VBN
of  ||| S:2937 E:2940 ||| IN
allopurinol  ||| S:2940 E:2952 ||| NN
or  ||| S:2952 E:2955 ||| CC
for  ||| S:2955 E:2959 ||| IN
whom  ||| S:2959 E:2964 ||| WP
allopurinol  ||| S:2964 E:2976 ||| RB
is  ||| S:2976 E:2979 ||| VBZ
contraindicated ||| S:2979 E:2994 ||| VBN
.  ||| S:2994 E:2996 ||| .
